Table 2.
DLT in Assessable Patients
Parameter, (n%) | Avelumab + Lorlatinib (n = 28) | Avelumab + Crizotinib (n = 12) |
---|---|---|
DLT | 2 (7) | 5 (42) |
ALT increased | 2 (7) | 2 (17) |
AST increased | 0 | 2 (17) |
ECG QT prolonged | 0 | 1 (8) |
Febrile neutropenia | 0 | 1 (8) |
Immune-mediated hepatitis | 0 | 1 (8) |
Rash | 0 | 1 (8) |
Note: Patients with more than one DLT are counted only once.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity; ECG, electrocardiogram.